People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotechnology, Pharmaceuticals, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. | — | Biotechnology | Series D+ | $632.6M | $3.2B | 2018 |
| Kura Oncology, Inc. | — | Biotechnology | Series D+ | $241.7M | $1.9B | 2024 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2012 |
| Sente Inc | — | Other Health Care | Series A | $20.6M | $171.2M | 2013 |
| Windsor Boys Racing, LLC | — | Other | Pre-Seed | $317K | $7.3M | 2017 |
Faheem Hasnain at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Faheem Hasnain on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Kristina Burow | 2 | 16 |
| Richard Lim | 1 | 14 |
| Amir Nashat | 1 | 14 |
| TROY WILSON | 1 | 7 |
| Robert Nelson | 1 | 7 |
| Magda Marquet | 1 | 6 |
| Doug Cole | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| HEIDI HENSON | 1 | 5 |
| Sheila Gujrathi | 1 | 5 |
| William Rastetter | 1 | 4 |
| Kleanthis Xanthopoulos | 1 | 4 |
| Michael Yi | 1 | 4 |
| YI LIU | 1 | 4 |
| PINGDA REN | 1 | 3 |
| Mary Szela | 1 | 3 |
| Marcus Boehm | 1 | 3 |
| James Schmidt | 1 | 3 |
| Philippe Schaison | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.